FLT3 and acute myeloid leukemia: Activating mutations of the FMS-like tyrosine kinase 3 (FLT3) occurring in about 30% of newly diagnosed AML play a pivotal role in diagnostic algorithms, prognostic stratification, and first line treatment of AML patients.